

Vector Borne Disease Control Program Monthly Reporting Format				
S.No	Program		In No	
	Name of District			
	Name of Block			
	Reporting Month			
1	Malaria			
1.1	Passive Surveillance	Total Population of the District/ Block		
1.2		Total no of OPD New Cases		
1.3		No of fever cases which attended the clinic		
1.4		Blood Slide (B/S) collected		
1.5		Blood Slide (B/S) Examined		
1.6		Blood Slide (B/S) positive		
1.7	Active	Blood Slide (B/S) Collected		
1.8		Blood Slide (B/S) Examined		
1.9		Blood Slide (B/S) Positive		
1.10	Mass Contact	Blood Slide (B/S) Collected		
1.11		Blood Slide (B/S) Examined		
1.12		Blood Slide (B/S) Positive		
1.13	Rapid Diagnostics Test (RDT)	No of Rapid Diagnostics Test (RDT) conducted		
1.14		No of Rapid Diagnostics tested found positive		
1.15	Species	Plasmodium Vivax (PV)		
1.16		Plasmodium Falciparum (PF)		
1.17		Mixed		
1.18	Age wise positive cases	Plasmodium Vivax	0-1	
1.19			1-4	
1.20			5-8	
1.21			9-14	
1.22			>= 15	
1.23		Plasmodium Falciparum	0-1	
1.24			1-4	
1.25			5-8	
1.26			9-14	
1.27			>= 15	
1.28	Radical Treatment	Complete		
1.29		Partial		
1.30		If Partial:-		
1.31		I . Under RT		
1.32		II. Pregnancy		
1.33		III. Gone Out		
1.34		IV. Refused		
1.35	Drugs	Chloroquine Consumed		
1.36		Primaquin Consumed		
1.37		Sulfaphadoxine + Pyrimethamine consumed		
1.38		Quinine Consumed		
1.39		ACT (Artemisinin combination Therapy) Consumed		
1.40		Mefloquine Consumed		
1.41	Focal Spray	Total Focal Spray room		
1.42	Entomological Indicators	Total breeding sites		
1.43		Density of mosquitoes		
1.44		Treated sites		
1.45		Total area of treated sides (in Square meter)		
1.46		Larvicides used		
1.47		Quantity of Larvicides		
1.48	No. of Deaths from Malaria	Total No. of Deaths		

2	Filaria		
2.1	Persons examined	Persons examined	
2.2		No positive for micro Filaria	
2.3		No positive for Disease	
2.4	No of persons blood slides collected at Night clinic	0-04 years (Male)	
2.5		0-04 years (Female)	
2.6		5-14 years (Male)	
2.7		5-14 years (Female)	
2.8		15-39 years (Male)	
2.9		15-39 years (Female)	
2.10		40 and above years (Male)	
2.11		40 and above years (Female)	
2.12	No of persons positive for Filaria at Night clinic	0-04 years (Male)	
2.13		0-04 years (Female)	
2.14		5-14 years (Male)	
2.15		5-14 years (Female)	
2.16		15-39 years (Male)	
2.17		15-39 years (Female)	
2.18		40 and above years (Male)	
2.19		40 and above years (Female)	
2.20	No of persons positive for Disease at Night clinic	0-04 years (Male)	
2.21		0-04 years (Female)	
2.22		5-14 years (Male)	
2.23		5-14 years (Female)	
2.24		15-39 years (Male)	
2.25		15-39 years (Female)	
2.26		40 and above years (Male)	
2.27		40 and above years (Female)	
2.28	No of persons blood slides collected at door to door survey	0-04 years (Male)	
2.29		0-04 years (Female)	
2.30		5-14 years (Male)	
2.31		5-14 years (Female)	
2.32		15-39 years (Male)	
2.33		15-39 years (Female)	
2.34		40 and above years (Male)	
2.35		40 and above years (Female)	
2.36	No of persons positive for Filaria at door to door survey	0-04 years (Male)	
2.37		0-04 years (Female)	
2.38		5-14 years (Male)	
2.39		5-14 years (Female)	
2.40		15-39 years (Male)	
2.41		15-39 years (Female)	
2.42		40 and above years (Male)	
2.43		40 and above years (Female)	
2.44	No of persons positive for Disease at door to door survey	0-04 years (Male)	
2.45		0-04 years (Female)	
2.46		5-14 years (Male)	
2.47		5-14 years (Female)	
2.48		15-39 years (Male)	
2.49		15-39 years (Female)	
2.50		40 and above years (Male)	
2.51		40 and above years (Female)	
2.52	No of patients given treatment	1-11 doses	
2.53		12 doses	

2.54		Total	
2.55	No of persons shown reaction		
2.56	Out of persons shown reaction, no of persons given remedial treatment		
2.57	No of untreated cases		
3	Dengue		
3.1	Suspected cases at Public Facilities	No of Suspected cases	
3.2	IgM ELISA (MAC ELISA) test	No of kits received	
3.3		No of kits used	
3.4		Sample tested	
3.5		Sample positive	
3.6	NS1 ELISA Test	No of kits received	
3.7		No of kits used	
3.8		Sample tested	
3.9		Sample positive	
3.10	Rapid Card test	No of kits received	
3.11		No of kits used	
3.12		Sample tested	
3.13		Sample positive	
3.14	Dengue confirmed cases	No of Dengue fever cases	
3.15		Dengue Hemorrhagic Fever	
3.16		Dengue Shock Syndrome	
3.17	Deaths reported from Public Facilities	No of deaths at public facilities	
3.18	Private Facilities	No of Suspected cases	
3.19		No of cases lab examination done	
3.20		IgM ELISA (MAC ELISA) test	
3.21		NS1 Elisa Test	
3.22		Rapid Card test	
3.23		No of cases positive	
3.24		IgM ELISA (MIC ELISA) test	
3.25		NS1 Elisa Test	
3.26		Rapid Card test	
3.27		# Dengue fever cases	
3.28	Dengue confirmed cases	# Dengue Hemorrhagic Fever	
3.29		# Dengue Shock Syndrome	
3.30	Deaths reported from Private Facilities	No of Deaths at Private Facilities	
4	Chikungunya		
4.1	No of suspected cases at Public Facilities		
4.2	IgM Elisa (MIC ELISA) test at Public facilities	No of kits received	
4.3		No of kits used	
4.4		Sample tested	
4.5		Sample positive	
4.6	No of suspected cases at Private Facilities		
4.7	IgM Elisa (MAC ELISA) test at Private facilities	Sample tested	
4.8		Sample positive	
5	Kalaazar		
5.1	Passive Case search of Kalaazar cases	No of Suspects cases of Kalaazar	
5.2		No of suspects cases referred from Pvt. Facilities	
5.3		No of suspects tested RK 16/ 39	
5.4		No of Positive cases of Kalaazar	
5.5		No tested HIV positive (of KA positive cases)	
5.6		No tested TB positive (of KA positive cases)	

5.7	Active case search of Kalaazar cases	No of Suspects cases of Kalaazar	
5.8		No of Persons Examined	
5.9		No of suspects tested RK 16/ 39	
5.10		No of Positive cases of Kalaazar	
5.11		No tested HIV positive (of KA positive cases)	
5.12		No tested TB positive (of KA positive cases)	
5.13	Active case search of Kalaazar cases (Camp Approach)	Total no of searches /camps organized	
5.14		No of villages covered	
5.15		Total persons screened	
5.16		No of MOs trained before search/ Camp	
5.17		No of ASHAs trained before search/ Camp	
5.18		No of suspects detected for Kalaazar	
5.19		No of suspects detected for PKDL	
5.20		No of cases confirmed for Kalaazar	
5.21		No of cases confirmed for PKDL	
6	Japanese Encephalitis (JE) and Acute Encephalitis Syndrome (AES)		
6.1	Japanese Encephalitis (JE) and Acute Encephalitis Syndrome (AES)	No of suspected cases/ AES	
6.2		No of sample tested	
6.3		No of samples positive for JE	
6.4		No of samples positive for other Diseases	
6.5		No of Handicaps from AES	
6.6		No of deaths from JE	
6.7		No of deaths from AES	